Browsing by Author "Yuce H."

Now showing 1 - 12 of 12

Comparing Health Care Resource Utilization and Costs Among Obese Patients in the Us Medicaid Population
(2016) Zhang, Q; Zhao, Y; Keshishian, A; Xie, L; Yuce H.; Başer, Onur
Objectives : To evaluate health care resource utilization and costs among obese patients in the U.S. Medicaid population.
Demographic and Socioeconomic Characteristics That Impact Selection of Oral Anticoagulants Among Non-Valvular Atrial Fibrillation Patients
(2016) Keshishian, A; Du, J; Xie, L; Yuce H.; Başer, Onur
...
Evaluating Asthma-Related Expenses and Health Care Resource Utilization Among Children in the Us Medicaid Population
(2016) Zhang, Q; Zhao, Y; Keshishian, A; Xie L; Yuce H.; Başer, Onur
...
Evaluation of the Burden of Parkinson’s Disease in Medicare and Linked Long Term Care Populations
(2015) Xie, L; Tan, H; Ogbomo, A; Wang, Y; Başer, Onur; Yuce H.
Objectives: To examine the economic burden and health care utilization forpatients diagnosed with Parkinson’s disease using linked data from Medicare andthe Long Term Care (LTC) Minimum Data Set (MDS). Methods: Patients wereincluded in the study if they had at least one diagnosis claim for Parkinson’s disease(International Classification of Diseases, 9thRevision, Clinical Modification code 332.xx) during the identification period (01JUL2008-31DEC2010). The first Parkinson’s disease diagnosis claim date was designated as the index date. Patients were requiredto be age ?65 and have continuous health plan enrollment with medical benefitsfor 6 months pre- and post-index date. Residents in a LTC facility were defined asstudy patients using two quarterly assessments recorded in the MDS during the6-month baseline period. Demographic and clinical characteristics and follow-uphealth care costs and utilizations were described. Results: After 1:1 matching,1,620 patients were included in each group (disease and control patients), and thebaseline characteristics were well-balanced. Patients with Parkinson’s diseasewere more likely to have inpatient stays (14.26% vs. 9.51%, p<0.0001), outpatientvisits (47.72% vs. 41.11%, p=0.0002), skilled nursing facility (SNF) visits (20.37% vs.4.51%, p<0.0001), hospice visits (8.64% vs. 1.36%, p<0.0001), and part D pharmacyvisit (62.65% vs. 53.33%, p<0.0001). Compared to control patients, higher all-causehealth care costs were also observed for Parkinson’s disease patients, includinginpatient costs ($2,451 vs. $1,301, p<0.0001), SNF costs ($2,503 vs. $778, p<0.0001),hospice costs ($1,164 vs. $245, p<0.0001), total outpatient costs ($4,477 vs. $1,304,p<0.0001), pharmacy costs ($695 vs. $1,399, p<0.0001) and total costs ($9,775 vs.$5,314, p<0.0001). Conclusions: During a period of 12 months, patients diagnosed with Parkinson’s disease had higher health care utilization and costs thanmatched control patients.
Examining the Economic Burden and Health Care Utilization of Menopausal Women in the U.s. Medicaid Population
(2015) Keshishian, A; Wang, Y; Xie, L; Başer, Onur; Yuce H.
...
Examining the Mortality and Readmission Rates of Patients Diagnosed With Stroke in the Us Medicare Population
(2016) Bashyal, R; Du, H; Li Wang; Yuce H.; Başer, Onur
...
Pmh13 - Examining Prevalence, Incidence and Mortality Rates Among Opioid-Dependent Patients in the U.s. Medicare Population
(2015) Li, L.; Shrestha, S.; Başer, Onur; Yuce H.; Li Wang
OBJECTIVES: To examine incidence, prevalence and mortality rates among opioiddependent patients in the U.S. Medicare population. METHODS: A study was performed for the period from January 1, 2008 through December 31, 2012 to determinethe prevalence, incidence and mortality rates among opioid-dependent patients(International Classification of Diseases, 9th Revision, Clinical Modification diagnosis codes 304.0x and 304.7x) in the U.S. Medicare population. Patients who hadcontinuous fee-for-service Medicare health plan enrollment for the calendar yearand at least 2 years prior were selected for the study. Age- and gender-adjustedopioid dependence prevalence and incidence rates were calculated via direct standardization to the U.S. population age ?65 years in 2010 using gender-specific agegroups. RESULTS: The annual adjusted prevalence of opioid-dependent patientsincreased from 0.06% in 2008 to 0.35% in 2012. Incidence rates increased from 0.06%in 2008 to 0.10% in 2012. Prevalence rates were higher among women than men everyyear during the study period. Patients age 65-69 years had the highest prevalencerates during 2008 (0.09%), 2009 (0.16%), 2010 (0.22%) and 2011 (0.32%). However, in2012, patients who were age 70-74 years had the highest prevalence rates (0.43%).North American Natives had the highest prevalence of opioid dependence comparedto all other races. The highest incidence of opioid dependence was observed inNevada in 2008 (221.9 per 100,000 person-years) and 2012 (222.1 per 100,000 personyears). The 30-day and 1-year mortality rates decreased by 10.5% (3.8 to 3.4 per 1,000person-years) and 25.4% (17.3 to 12.9 per 1,000 person-years), respectively, from 2008to 2012. CONCLUSIONS: Opioid dependence incidence and prevalence decreasedfrom 2008 to 2012; however, opioid dependence-related mortality rates increased.
Pmh15 - Prevalence and Incidence Rates Among Alcohol-Dependent Patients in the Us Medicare Population
(2015) Li, L,; Shrestha, S.; Başer, Onur; Yuce H.; Li Wang
OBJECTIVES: To examine incidence and prevalence rates among alcohol-dependentpatients in the U.S. Medicare population. METHODS: A prospective study was performed from 01JAN2008 through 31DEC2012 to determine the prevalence and incidence of patients diagnosed with alcohol dependence (International Classificationof Diseases, 9th Revision, Clinical Modification diagnosis code 303) in the U.S.Medicare population. Patients were required to have continuous enrollment in afee-for-service Medicare health plan during the calendar year and at least 2 yearsprior. The age- and gender-adjusted prevalence and incidence (overall and ageand gender-specific) rates of alcohol-dependent patients were calculated by directstandardization to the U.S. population age ?65 years in 2010. RESULTS: The annualadjusted overall prevalence rate increased from 0.30% in 2008 to 1.05% in 2012,whereas the annual overall incidence rate decreased from 0.30% in 2008 to 0.20%in 2012. Alcohol dependence prevalence and incidence rates were higher amongmen than women every year. Patients age 65-69 years had the highest prevalencerates during 2008 (0.43%) and 2009 (0.63%), whereas in 2010 (0.82%), 2011 (1.14%) and2012 (1.43%), patients age 70-74 years had the highest prevalence rates. Prevalencerates grew steadily among all age groups from 2008 to 2012. The highest alcoholdependence incidence rate was observed in the Virgin Islands (917.6 per 100,000person-years) in 2008, whereas in 2012, Wyoming (409.3 per 100,000 person-years)had the highest incidence rate. CONCLUSIONS: Increasing prevalence and decreas ing incidence of alcohol dependence was observed from 2008 to 2012. In addition,men were more likely to have alcohol dependence than women.
Pms37 - Health Care Cost Burden and Demographic Distribution of Patients Diagnosed With Psoriatic Arthritis in the Us Medicare Population
(2015) Li, L; Mao, X; Shrestha, S; Başer, Onur; Yuce H.; Li Wang
OBJECTIVES: To investigate the health care cost burden and demographic distributionof patients diagnosed with psoriatic arthritis (PSA) in the Medicare fee-for-service(FFS) Dataset. METHODS: A retrospective database analysis was performed usingthe 100% Medicare FFS Datasets from October 1, 2008 through December 31, 2012.Patients diagnosed with PSA were identified using International Classification ofDiseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis code 696.0, andthe index date was the date of the initial diagnosis. All patients were required to havecontinuous medical and pharmacy benefits 1-year pre- and post-index date. Healthcare costs and utilization during the baseline (1 year before the diagnosis date) andfollow-up (1 year after the diagnosis date) periods were calculated. RESULTS: Usingthe aforementioned criteria, 11,324 PSA patients were identified. The average ageat diagnosis was 74 years, 66.10% of patients were women and almost 92.36% werewhite. The majority of patients resided in the South U.S. region (39.01%). Diabetes(33.84%), chronic obstructive pulmonary disease (29.04%) and cerebrovascular disease(17.36%) were the main comorbidities observed during the baseline period. Duringthe follow-up period, 62.96% of patients had inpatient admissions, 47.29% had emergency room visits, 91.67% had outpatient office visits, 91.67% had outpatient visitsand 58.03% had pharmacy visits, costing, on average, $23,960, $237, $5,015, $5,252and $7,335, respectively. The average total cost of PSA patients was $36,548. The fivemost commonly prescribed medications for PSA were methotrexate sodium (4.54%),prednisone (3.37%), levothyroxine sodium (2.59%), hydrocodone bit/acetaminophen(2.43%) and simvastatin (2.11%). CONCLUSIONS: PSA patient demographic and healthcare cost information was obtained and the most commonly prescribed PSA medications were identified.
Pms38 - Demographic Distribution and Economic Burden of Patients Diagnosed With Rheumatoid Arthritis in the Us Medicare Population
(2015) Li, L; Mao, X; Shrestha, S; Başer, Onur; Yuce H.; Wang, Li
OBJECTIVES: To determine the demographic distribution and health care burden ofpatients diagnosed with rheumatoid arthritis (RA) using Medicare fee-for-service(FFS) data. METHODS: A retrospective analysis was performed using the 100%Medicare FFS datasets from October 1, 2008 through December 31, 2012. Patientsdiagnosed with RA were identified using International Classification of Diseases,9th Revision, Clinical Modification diagnosis code 714, and the first diagnosis datewas designated as the index date. All patients were required to have continuousmedical and pharmacy benefits 1 year pre- (baseline period) and post-index date(follow-up period). Health care resource utilization and costs during the baseline andfollow-up periods were calculated. RESULTS: Using Medicare FFS data, 112,550 RApatients were identified. The average age at diagnosis was 76 years, and 72.54% ofpatients were women and 83.94% were white. The most common baseline comorbidities were diabetes (35.48%), followed by chronic obstructive pulmonary disease(30.83%) and cerebrovascular disease (21.50%). During the follow-up period, 66.35%of patients had inpatient admissions, 49.01% had emergency room visits, 87.93%had outpatient office visits, 87.93% had outpatient visits and 61.67% had pharmacyvisits and costs were, on average, $26,510, $256, $4,204, $4,460 and $6,249, respectively. The average total costs incurred by RA patients were $37,219. The five mostcommonly-prescribed medications prescribed to treat RA were prednisone (3.40%),levothyroxine sodium (2.63%), hydrocodone bit/acetaminophen (2.39%), furosemide(2.13%) and omeprazole (2.13%). CONCLUSIONS: RA patient demographic distributions and RA-related health care cost information was obtained and the mostcommonly prescribed medications to treat RA were identified.
Pnd30 - Health Care Resource Utilizations and Costs Among Migraine Patients in the Us Medicaid Population
(2015) Huang, A; Shrestha, S; Başer, Onur; Yuce H.; Wang, Li
OBJECTIVES: To examine the health care resource utilizations and costs amongmigraine patients in the U.S. Medicaid population. METHODS: Migraine patientswere identified (International Classification of Disease, 9th Revision, ClinicalModification [ICD-9-CM] diagnosis code 346) using Medicaid data from January 01,2009 through December 31, 2009. The first diagnosis date was designated as theindex date, and patients were required to have at least a 1-year baseline (pre-indexdate) and 1-year follow-up (post-index date) period. A comparison cohort was created for patients without a migraine diagnosis during the study period, using 1:1propensity score matching to control for age, region, gender and baseline CharlsonComorbidity Index score. The comparison cohort’s index date was chosen at random to minimize selection bias. Patients in both cohorts were required to be age?18 years and have continuous medical and pharmacy benefits 1-year pre- andpost-index date. Study outcomes (health care resource utilizations and costs) werecompared between the migraine and comparison cohorts. RESULTS: After applyingPSM, 380,751 patients were assigned to each cohort, and baseline characteristicswere well-balanced. A higher percentage of patients with migraines had inpatientstays (21.53% vs. 11.00%, p<0.0001), other therapy (99.88% vs. 65.78%, p<0.001) andpharmacy visit claims (90.52% vs. 48.35%, p<0.0001), compared to those without amigraine diagnosis. The patients in the migraine cohort also incurred significantlyhigher other therapy ($4,111 vs. $2,312, p<0.0001) and pharmacy visit costs ($1,074vs. $512, p<0.0001) than those in the comparison cohort. CONCLUSIONS: Migrainepatients incurred significantly higher costs and had higher health care resourceutilizations than those without migraines
Trends in Prevalence and Incidence Rates of Type 2 Diabetes Mellitus in the Medicare Population
(2015) Xie, L; Wang, Y; Tan, H; Ogbomo, A; Başer, Onur; Yuce H.
...